Skip to main content
. Author manuscript; available in PMC: 2020 Feb 28.
Published in final edited form as: Nature. 2019 Jul 10;571(7766):576–579. doi: 10.1038/s41586-019-1382-1

Extended Data Fig. 8: PARP inhibitor therapy by BRCA1/2 mutation origin and zygosity.

Extended Data Fig. 8:

A single PARP inhibitor outcome analysis of all four BRCA genotypes as independent classes (BRCA1/2 mutational origin and zygosity) with BRCA-associated cancer types (as in main text Fig. 4). All four classes of BRCA-mutant patients (see legend, as indicated) achieve significantly greater clinical benefit to PARP inhibitor therapy than do treated patients with WT BRCA tumors [BRCA1/2-mutant classes are germline carrier somatic heterozygous (HR=0.39, 0.21–0.72, p-value=0.003); germline carrier, somatic biallelic (HR=0.5, 0.35–0.72, p-value=2e-4); somatic heterozygous LoF (HR=0.5, 0.26–0.95, p-value=0.03); and somatic LoF biallelic (HR=0.34, 0.16–0.72, p-value=0.005).